Abstract

The translocation of YAP from the cytoplasm to the nucleus is critical for its activation and plays a key role in tumor progression. However, the precise molecular mechanisms governing the nuclear import of YAP are not fully understood. In this study, we have uncovered a crucial role of SOX9 in the activation of YAP. SOX9 promotes the nuclear translocation of YAP by direct interaction. Importantly, we have identified that the binding between Asp-125 of SOX9 and Arg-124 of YAP is essential for SOX9-YAP interaction and subsequent nuclear entry of YAP. Additionally, we have discovered a novel asymmetrical dimethylation of YAP at Arg-124 (YAP-R124me2a) catalyzed by PRMT1. YAP-R124me2a enhances the interaction between YAP and SOX9 and is associated with poor prognosis in multiple cancers. Furthermore, we disrupted the interaction between SOX9 and YAP using a competitive peptide, S-A1, which mimics an α-helix of SOX9 containing Asp-125. S-A1 significantly inhibits YAP nuclear translocation and effectively suppresses tumor growth. This study provides the first evidence of SOX9 as a pivotal regulator driving YAP nuclear translocation and presents a potential therapeutic strategy for YAP-driven human cancers by targeting SOX9-YAP interaction.

Details

Title
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors
Author
Qian, Hui 1 ; Ding, Chen-Hong 2 ; Liu, Fang 1 ; Chen, Shi-Jie 3 ; Huang, Chen-Kai 4 ; Xiao, Meng-Chao 2 ; Hong, Xia-Lu 1 ; Wang, Ming-Chen 3 ; Yan, Fang-Zhi 1 ; Ding, Kai 1 ; Cui, Ya-Lu 1 ; Zheng, Bai-Nan 1 ; Ding, Jin 5 ; Luo, Cheng 3   VIAFID ORCID Logo  ; Zhang, Xin 1 ; Xie, Wei-Fen 1 

 Naval Medical University, Department of Gastroenterology, Changzheng Hospital, Shanghai, China (GRID:grid.73113.37) (ISNI:0000 0004 0369 1660) 
 Tongji University, Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535) 
 Chinese Academy of Sciences, Drug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309) 
 First Affiliated Hospital of Nanchang University, Department of Gastroenterology, Nanchang, China (GRID:grid.412604.5) (ISNI:0000 0004 1758 4073) 
 Naval Medical University, Clinical Cancer Institute, Center for Translational Medicine, Shanghai, China (GRID:grid.73113.37) (ISNI:0000 0004 0369 1660) 
Pages
96
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
ISSN
20959907
e-ISSN
20593635
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3048575951
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.